Back

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Contra

8 November 2019 (15:00 - 15:10)
Organised by:
Congress Presentation Part of: Controversies in 2019 Valvular Heart Disease ESC Premium Access ESC Asia with APSC & AFC

About the speaker

Photo
Associate Professor Kenny Yoong Kong Sin

National Heart Centre Singapore, Singapore (Singapore)

5 More presentations in this session

Presentation thumbnail
Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure - Pro.
Associate Professor D. Sim (Singapore, SG)
Slides Video
Presentation thumbnail
Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure- Contra.
Professor J. Cleland (Glasgow, GB)
Slides Video
Presentation thumbnail
Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure concluding discussion.
Presentation thumbnail
PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Pro.
Professor M. Marwan (Erlangen, DE)
Slides Video
Presentation thumbnail
PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Concluding discussion.
Video

Access the full session

Session thumbnail
Controversies in 2019

The Event

Event poster

ESC Asia with APSC & AFC

8 November 2019 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Coronary artery bypass grafting versus percutaneous coronary intervention for left main disease in chronic kidney disease patients: A meta-analysis
28 August 2020
thumbnail
Congress Presentation
Discussions.
28 August 2022
thumbnail
Congress Presentation
One stent versus two stents for distal LM PCI: insights from the experience of a high volume center
28 August 2020
thumbnail
Webinar
Percutaneous interventions in patients with coronary artery disease and specific clinical conditions - IC Core Curriculum 6
9 November 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources